Check-Cap (MBAI) Stock Price, News & Analysis

Company Overview

Check-Cap Ltd. was an Israel-based medical diagnostics company focused on developing noninvasive technologies for colorectal cancer screening. Its lead product, C-Scan, was an ingestible, capsule-based imaging system designed to examine the colon for polyps and other abnormalities without requiring the extensive bowel preparation typically associated with conventional colonoscopy.

The C-Scan system was intended to combine a disposable capsule with an external tracking and data-collection system, allowing physicians to review images of the gastrointestinal tract after the capsule passed through the body. The technology remained a development-stage product and was subject to clinical testing and regulatory review rather than being an established commercial screening service.

Check-Cap conducted its research and development activities primarily in Israel and pursued potential regulatory and commercial opportunities in the United States and other international markets. The company’s historical Nasdaq symbol was CHEK; the symbol MBAI does not appear to correspond to Check-Cap, so the company and ticker designation should be independently verified.

Key Stats

• Today's Range: $6.31 to $6.39
• 50-Day Range: $6.30 to $10.01
• 52-Week Range: $6.01 to $27.44
• Volume: 6,265 shs
• Average Volume: 29,244 shs
• Market Capitalization: $8.82 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Check-Cap Stock Analysis - MarketRank™

Check-Cap scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Check-Cap has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Check-Cap has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Check-Cap is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Check-Cap is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Check-Cap has a P/B Ratio of 1.94. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.89% of the float of Check-Cap has been sold short.

Short Interest Ratio / Days to Cover

Check-Cap has a short interest ratio ("days to cover") of 1.23, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Check-Cap has recently decreased by 3.55%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Check-Cap does not currently pay a dividend.

Dividend Growth

Check-Cap does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Check-Cap this week, compared to 2 articles on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Check-Cap insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.48% of the stock of Check-Cap is held by insiders.

Percentage Held by Institutions

1.07% of the stock of Check-Cap is held by institutions.

Company Calendar

• Today: 9/19/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:MBAI
• CIK: 1610590
• Web: www.mbody.ai
• Phone: 972-4-8303400
• Fax: 972-4821-1267
• Employees: 85
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.05
• Quick Ratio: 0.05

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: $3.99 per share
• Price / Cash Flow: 1.60
• Book Value: $3.30 per share
• Price / Book: 1.94

Miscellaneous

• Outstanding Shares: 1,380,000
• Free Float: 1,368,000
• Market Cap: $8.82 million
• Optionable: N/A
• Beta: 0.67